Has_circ_0010220 regulates the miR-574-3p/IL-6 axis to increase doxorubicin resistance in osteosarcoma

Gu, Yanglin; Wang, Guangchang; Ran, Baocai

doi:10.1177/09603271221131307

Cited by 3 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, hsa_circ_0010220 can improve the levels of miR-574-3P and IL-6, achieving the goal of resistance to DOX (Gu et al, 2022).…”

Section: Circrnas As Supporters Of Drug Resistance In Osmentioning

confidence: 99%

See 1 more Smart Citation

Deciphering chemoresistance in osteosarcoma: Unveiling regulatory mechanisms and function through the lens of noncoding RNA

Chen,

Gong,

Zhou

et al. 2024

Drug Development Research

View full text Add to dashboard Cite

Osteosarcoma (OS) is a primary malignant bone tumor and is prevalent in children, adolescents, and elderly individuals. It has the characteristics of high invasion and metastasis. Neoadjuvant chemotherapy combined with surgical resection is the most commonly used treatment for OS. However, the efficacy of OS is considerably diminished by chemotherapy resistance. In recent years, noncoding RNAs (ncRNAs), including microRNAs, long noncoding RNAs, and circular RNAs, are hot topics in the field of chemotherapy resistance research. Several studies have demonstrated that ncRNAs are substantially associated with chemoresistance in OS. Thus, the present study overviews the abnormally expressed ncRNAs in OS and the molecular mechanisms involved in chemoresistance, with an emphasis on their function in promoting or inhibiting chemoresistance. ncRNAs are expected to become potential therapeutic targets for overcoming drug resistance and predictive biomarkers in OS, which are of great significance for enhancing the therapeutic effect and improving the prognosis.

show abstract

“…Moreover, hsa_circ_0010220 can improve the levels of miR-574-3P and IL-6, achieving the goal of resistance to DOX (Gu et al, 2022).…”

Section: Circrnas As Supporters Of Drug Resistance In Osmentioning

confidence: 99%

“…Hsa_circ_0003496 can sponge miR‐370 and subsequently target KLF12 to promote resistance to DOX (Xie, Liang, et al, 2020). Moreover, hsa_circ_0010220 can improve the levels of miR‐574‐3P and IL‐6, achieving the goal of resistance to DOX (Gu et al, 2022).…”

Section: Circrnas Associated With Drug Resistance In Osmentioning

confidence: 99%

Deciphering chemoresistance in osteosarcoma: Unveiling regulatory mechanisms and function through the lens of noncoding RNA

Chen,

Gong,

Zhou

et al. 2024

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…This may provide new insights into the role of circpvt1 as a biomarker for the diagnosis and treatment of OS. Gu et al 45 showed that has_circ_0010220 increased DOX-resistance in OS by miR-574-3p/IL-6 axis regulation. Reducing DOX resistance in vitro was achieved by silencing Has_circ_0010220.…”

Section: Application Of Circrna In the Diagnosis And Treatment Of Ost...mentioning

confidence: 99%

Recent Advances of Circular RNAs as Biomarkers for Osteosarcoma

Wu¹,

Zheng²,

He³

et al. 2023

IJGM

View full text Add to dashboard Cite

Osteosarcoma is the most common primary malignant bone tumor in young adult, which is prone to early metastasis and poor prognosis. The current treatment methods need to be improved. Circular RNA is a covalently blocked circular, non-coding RNA that plays an essential role in the occurrence, development, clinical diagnosis, and treatment of various diseases. Recently, an increasing number of circRNAs have been identified in osteosarcoma. Understanding its role in osteosarcoma is conducive to the early detection, diagnosis, and treatment of osteosarcoma. In this paper, we reviewed the mechanism of action of circular RNA in the occurrence and development of osteosarcoma and its clinical application in recent years.

show abstract

Osteosarcoma in a ceRNET perspective

Mosca,

Alessio,

Di Paola

et al. 2024

J Biomed Sci

View full text Add to dashboard Cite

Osteosarcoma (OS) is the most prevalent and fatal type of bone tumor. It is characterized by great heterogeneity of genomic aberrations, mutated genes, and cell types contribution, making therapy and patients management particularly challenging. A unifying picture of molecular mechanisms underlying the disease could help to transform those challenges into opportunities.This review deeply explores the occurrence in OS of large-scale RNA regulatory networks, denominated “competing endogenous RNA network” (ceRNET), wherein different RNA biotypes, such as long non-coding RNAs, circular RNAs and mRNAs can functionally interact each other by competitively binding to shared microRNAs. Here, we discuss how the unbalancing of any network component can derail the entire circuit, driving OS onset and progression by impacting on cell proliferation, migration, invasion, tumor growth and metastasis, and even chemotherapeutic resistance, as distilled from many studies. Intriguingly, the aberrant expression of the networks components in OS cells can be triggered also by the surroundings, through cytokines and vesicles, with their bioactive cargo of proteins and non-coding RNAs, highlighting the relevance of tumor microenvironment. A comprehensive picture of RNA regulatory networks underlying OS could pave the way for the development of innovative RNA-targeted and RNA-based therapies and new diagnostic tools, also in the perspective of precision oncology.

show abstract

Has_circ_0010220 regulates the miR-574-3p/IL-6 axis to increase doxorubicin resistance in osteosarcoma

Cited by 3 publications

References 22 publications

Deciphering chemoresistance in osteosarcoma: Unveiling regulatory mechanisms and function through the lens of noncoding RNA

Deciphering chemoresistance in osteosarcoma: Unveiling regulatory mechanisms and function through the lens of noncoding RNA

Recent Advances of Circular RNAs as Biomarkers for Osteosarcoma

Osteosarcoma in a ceRNET perspective

Contact Info

Product

Resources

About